Project Details
| Status | Active |
|---|---|
| Effective start/end date | 5/13/20 → 5/12/25 |
Funding
- Eli Lilly & Company: $11,991.54
Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2
- Cohn, Steven (PI)
Project: Other project